Google
MDGL — MADRIGAL PHARMACEUTICALS INC (Healthcare >> Biotechnology)
MDGL FAQ
What is MDGL's ROE?
MADRIGAL PHARMACEUTICALS INC reports a Return on Equity (ROE) of -56.94%.
What is MDGL's dividend yield?
MADRIGAL PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is MDGL's Deepscope Quality Score?
Deepscope rates MDGL's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MDGL?
Deepscope's AI Timing Score for MDGL is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MDGL belong to?
MADRIGAL PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 486.98
Price
-5.85
(-1.19%)
Day Change
|
|
|---|
MDGL, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 486.98 |
| PBV / Sector |
20.79 / 4.63
|
| Earning Per Share | -13.34 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
134.03 M
GREAT
|
| Average 1W Daily Value |
119.70 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:03 |
| Symbol | MDGL |
| Name | MADRIGAL PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 23.06 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11,297.27 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Four Tower Bridge, West Conshohocken, PA, United States, 19428
Phone: 267 824 2827
Website: https://www.madrigalpharma.com
Employees: 915
Sector: Healthcare >> Biotechnology
Description: Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
